Menu
← Oncology Approval Tracker
FDA DECISION ·
Enhertu → THP
fam-trastuzumab deruxtecan-nxki followed by a taxane, trastuzumab and pertuzumab · Daiichi Sankyo
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Neoadjuvant treatment for adults with stage II or III HER2-positive breast cancer, defined as IHC 3+ or ISH-positive on an FDA-authorized test.
LAMPGEN ANALYSIS
Why it matters
This moves an ADC into treatment before surgery. Pathologic complete response at surgery addresses a different question from long-term recurrence and survival.
What research teams should watch
Capture pretreatment HER2 and stage, the transition to THP and surgical pathology. Keep the neoadjuvant protocol distinct from the residual-disease adjuvant indication.
PRIMARY RECORDS